Drug-induced liver injury (DILI), caused by drugs, herbal agents or nutritional supplements,
is a major issue for patients and the pharmaceutical industry. It has been a leading cause of …

Drug‐induced liver injury (DILI) is a leading cause of acute liver failure in the US and less
severe liver injury worldwide. It is also one of the major reasons of drug withdrawal from the …

Safety is one of the important factors constraining the distribution of clinical drugs on the
market. Drug-induced liver injury (DILI) is the leading cause of safety problems produced by …

As one of the leading causes of drug failure in clinical trials, drug-induced liver injury (DILI)
seriously impeded the development of new drugs. Assessing the DILI risk of drug candidates …

As a critical issue in drug development and postmarketing safety surveillance, drug-induced
liver injury (DILI) leads to failures in clinical trials as well as retractions of on-market …

Drug induced liver injury (DILI) is the prime cause of liver disfunction which may lead to mild
non-specific symptoms to more severe signs like hepatitis, cholestasis, cirrhosis and …

Drug-induced liver injury (DILI) remains one of the challenges in the safety profile of both
authorized and candidate drugs, and predicting hepatotoxicity from the chemical structure of …

Drug discovery is a costly process which usually takes more than 10 years and billions of
dollars for one successful drug to enter the market. Despite all the safety tests, drugs may …

Drug-induced liver injury (DILI) is one the rare adverse drug reaction (ADR) and
multifactorial endpoints. Current preclinical animal models struggle to anticipate it, and in …

Drug-induced liver injury (DILI) is a major issue for both patients and pharmaceutical
industry due to insufficient means of prevention/prediction. In the current work we present a …